ÂÜÀòÂÒÂ×

Sarah Nemec, Vice President, Finance, joined Bolt Biotherapeutics in 2020, bringing more than 20 years as a senior finance leader in the life science industry to the company. At Bolt, she is responsible for all aspects of the company’s financial planning, accounting, and reporting. Ms. Nemec played a key role in Bolt’s initial public offering and spearheaded all activities necessary to establish the company’s financial management infrastructure, key reporting systems and processes. Prior to joining Bolt, she served as the vice president, principal accounting executive for BioElectron Technology Corp., where she led accounting and cash management for the company through the sale and transition of its assets to PTC Therapeutics. Previously, Ms. Nemec served as the director, financial reporting for JDA Software (now Blue Yonder) and associate director, SEC reporting for Affymetrix (acquired by Thermo Fisher Scientific).

Ms. Nemec began her career as an auditor in the financial services and life science practice at Ernst & Young, LLP. Ms. Nemec is a certified public accountant and earned her bachelor’s and master’s degrees in accounting from Ohio University.